Weekly Recap: OASIZ—301 dazodalibep meets ESSDAI and Topline lacks detail

Amgen Inc. (NASDAQ:AMGN) said Phase 3 OASIZ—301 met its primary ESSDAI endpoint at Week 48 with dazodalibep showing benefits by Week 4 and mostly mild—moderate AEs, lowering clinical risk for its Immunology and Inflammation asset from the 2023 Horizon deal while OASIZ—303 reads out in Q4 2026.Previ…